The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statins.
The objectives of this review are to discuss the role of cytochrome P450 (CYP450) isoforms in drug metabolism, to explain differences in metabolism among the HMG-CoA reductase inhibitors (HMGs, statins), to review drug-drug and drug-food interaction studies dealing with the HMGs, to present case reports dealing with HMG-related myopathy, to discuss major clinical implications of these case reports and to express an opinion of use of HMGs in clinical practice.
Worz
C R
CR
Department of Pharmacy, University of Cincinnati, Ohio, USA. crw@skilledcare.com
Bottorff
M
M
D000368:Aged; D002986:Clinical Trials as Topic; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D004110:Diltiazem / Q000494:pharmacology; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D017408:Guidelines as Topic; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000494:pharmacology*; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D007527:Isoenzymes / Q000378:metabolism; D017964:Itraconazole / Q000494:pharmacology; D008148:Lovastatin / Q000037:antagonists & inhibitors / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009135:Muscular Diseases / Q000139:chemically induced; D017035:Pravastatin / Q000037:antagonists & inhibitors; D012206:Rhabdomyolysis / Q000139:chemically induced; D019821:Simvastatin / Q000037:antagonists & inhibitors / Q000494:pharmacology
D065607:Cytochrome P-450 Enzyme Inhibitors; D004791:Enzyme Inhibitors; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D007527:Isoenzymes; D017964:Itraconazole; D003577:Cytochrome P-450 Enzyme System; D008148:Lovastatin; D019821:Simvastatin; D004110:Diltiazem; D017035:Pravastatin